Rolf Brekken

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. doi request reprint PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer
    Katherine T Ostapoff
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390, USA
    Mol Cancer Ther 12:1190-201. 2013
  2. pmc BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer
    Bercin Kutluk Cenik
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Mol Cancer Ther 12:992-1001. 2013
  3. pmc SPARC: a matricellular regulator of tumorigenesis
    Shanna A Arnold
    Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology and Departments of Surgery and Pharmacology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390 8593 USA
    J Cell Commun Signal 3:255-73. 2009
  4. pmc Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
    Niranjan Awasthi
    Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    BMC Cancer 11:15. 2011
  5. pmc GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer
    Kristi D Lynn
    Division of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 76259, USA
    BMC Cancer 10:397. 2010
  6. pmc The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
    Sean P Dineen
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390 8593, USA
    BMC Cancer 8:352. 2008

Research Grants

Collaborators

  • Thomas J Kodadek
  • Katherine T Ostapoff
  • Bercin Kutluk Cenik
  • Niranjan Awasthi
  • Roderich E Schwarz
  • Kristi D Lynn
  • Shanna A Arnold
  • Sean P Dineen
  • Keith Dredge
  • Stefan Hinz
  • David E Gerber
  • Margaret A Schwarz
  • Jason E Toombs
  • Amanda Kirane
  • Christina L Roland
  • Diego H Castrillon
  • D Gomika Udugamasooriya
  • Adam W Beck
  • Roni Mamluk
  • Andrew F Miller
  • Juliet G Carbon
  • Laura A Sullivan
  • Henry Wong

Detail Information

Publications6

  1. doi request reprint PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer
    Katherine T Ostapoff
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390, USA
    Mol Cancer Ther 12:1190-201. 2013
    ..These results highlight the potent antitumor activity of PG545 and support the further exploration of heparanase inhibitors as a potential clinical strategy for the treatment of PDAC...
  2. pmc BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer
    Bercin Kutluk Cenik
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Mol Cancer Ther 12:992-1001. 2013
    ..The absence of EMT induction, which has been implicated in resistance to antiangiogenic therapies, is noteworthy. Together, these results warrant further clinical studies of BIBF 1120...
  3. pmc SPARC: a matricellular regulator of tumorigenesis
    Shanna A Arnold
    Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology and Departments of Surgery and Pharmacology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390 8593 USA
    J Cell Commun Signal 3:255-73. 2009
    ..We aim to provide insight into how a matricellular protein such as SPARC might generate paradoxical, yet relevant, tumor outcomes in order to unify an apparently incongruent collection of scientific literature...
  4. pmc Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
    Niranjan Awasthi
    Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    BMC Cancer 11:15. 2011
    ..Smac is an endogenous IAP-antagonist, which renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management...
  5. pmc GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer
    Kristi D Lynn
    Division of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 76259, USA
    BMC Cancer 10:397. 2010
    ..We have reported previously the development of an antagonistic VEGFR2 peptoid (GU40C4) that has promising anti-angiogenic activity in vitro and in vivo...
  6. pmc The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
    Sean P Dineen
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390 8593, USA
    BMC Cancer 8:352. 2008
    ..This small protein is based on a human fibronectin domain and has beneficial properties in that it is fully human, stable, and is produced in bacteria. CT-322 binds to and inhibits activation of VEGFR2...

Research Grants4